Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025.

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

He will then hand off the role to Dr. Johanna Bendell, who will join the Pfizer team in 2025. Dansey has years of experience leading clinical development efforts of notable cancer medications like ...

(Reuters) -Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce ...

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025.

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...